Jazz Pharmaceuticals
JAZZ
503 hedge funds and large institutions have $8.01B invested in Jazz Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 61 funds opening new positions, 161 increasing their positions, 202 reducing their positions, and 53 closing their positions.
448% more call options, than puts
Call options by funds: $130M | Put options by funds: $23.7M
22% more capital invested
Capital invested by funds: $6.57B → $8.01B (+$1.44B)
15% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 53
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
0% more funds holding
Funds holding: 502 → 503 (+1)
2.06% less ownership
Funds ownership: 102.22% → 100.17% (-2.1%)
20% less repeat investments, than reductions
Existing positions increased: 161 | Existing positions reduced: 202
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Goldentree Asset Management
New York
|
+$136M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$44.8M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$35.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$31.4M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$27.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$84M |
| 2 |
Millennium Management
New York
|
-$47.1M |
| 3 |
PL
Perpetual Ltd
Sydney, New South Wales,
Australia
|
-$34.2M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$30M |
| 5 |
Morgan Stanley
New York
|
-$29.8M |
JAZZ Hedge Fund Activity: Q3 2025 in Review
503 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q3 2025, worth a combined $8.01B — up 22% from $6.57B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new JAZZ positions and 53 closed out — a net gain of 8 holders — while 161 added to existing stakes and 202 trimmed.
The largest buyer was Goldentree Asset Management, opening a new position worth an estimated $136M. The largest seller was Vestal Point Capital, cutting an estimated $84M.
- 503 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q3 2025, up from 502 in Q2 2025.
- Funds reported $8.01B of Jazz Pharmaceuticals stock for Q3 2025, up 22% quarter-over-quarter.
- 61 funds opened new Jazz Pharmaceuticals positions in Q3 2025 and 53 closed out, a net change of +8 holders.
- The largest Jazz Pharmaceuticals buyer in Q3 2025 was Goldentree Asset Management, an estimated $136M added.
- The largest Jazz Pharmaceuticals seller in Q3 2025 was Vestal Point Capital, an estimated $84M sold.
Based on aggregated 13F filings for Q3 2025.